Stay updated on AFM24 + Atezolizumab in EGFR+ Cancers Clinical Trial
Sign up to get notified when there's something new on the AFM24 + Atezolizumab in EGFR+ Cancers Clinical Trial page.

Latest updates to the AFM24 + Atezolizumab in EGFR+ Cancers Clinical Trial page
- Check6 days agoChange DetectedShow glossary feature added; two PDFs (Study Protocol and Statistical Analysis Plan) were added under Study Documents with their dates, and several metadata timestamps (Last Verified, Last Update, Results posting dates) were updated.SummaryDifference55%

- Check13 days agoNo Change Detected
- Check21 days agoChange DetectedRevision: v3.3.4 was added and v3.3.3 was removed.SummaryDifference0.0%

- Check42 days agoChange DetectedAdded a Locations section listing study sites (California, Illinois, Maryland) and updated the page to revision v3.3.3. The HHS Vulnerability Disclosure link was removed.SummaryDifference0.4%

- Check64 days agoChange DetectedThe page revision indicator was updated from v3.3.1 to v3.3.2.SummaryDifference0.0%

- Check71 days agoChange DetectedThe page shows a minor version revision from v3.2.0 to v3.3.1, with no changes to study content, eligibility criteria, or listed locations. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check78 days agoChange DetectedRemoved the government funding lapse notice; no core study content or eligibility information was changed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

Stay in the know with updates to AFM24 + Atezolizumab in EGFR+ Cancers Clinical Trial
Enter your email address, and we'll notify you when there's something new on the AFM24 + Atezolizumab in EGFR+ Cancers Clinical Trial page.